WegoSlim vs MounjaSlim: Choosing Your Doctor-Led Weight Program
Semaglutide and tirzepatide compared honestly — mechanism, results, side effects and fit.
Quick answer
WegoSlim or MounjaSlim: how is the choice made?
WegoSlim uses a semaglutide-based plan, while MounjaSlim uses a tirzepatide-based plan. They act through different hormone pathways and are not chosen from average study results alone. A physician should first review the indication, medical history, contraindications, current medicines, previous response, side effects, access and follow-up needs. Neither programme guarantees a fixed amount or speed of weight loss.
- Suitable for
- Adults who meet prescribing criteria and can follow a physician-led titration and monitoring plan.
- What to expect
- Response varies with medicine, dose, tolerance, nutrition, activity and duration of treatment.
- Risks
- Gastrointestinal effects are common; contraindications, interactions and serious symptoms require medical review.
- Downtime
- No procedural downtime, although adjustment symptoms may affect meals, hydration and routine.
- When to see a doctor
- Before choosing or switching a programme, and promptly for persistent vomiting, dehydration or severe abdominal pain.
Both of Hori's weight programs are weekly-injection GLP-1 plans run by a doctor — but they use different medicines. WegoSlim is built on semaglutide (a GLP-1 agonist); MounjaSlim on tirzepatide (a dual GIP + GLP-1 agonist). Here is how they differ in practice, without the hype.
Same family, different engines
Both medicines mimic gut hormones that regulate appetite: meals feel satisfying sooner, cravings quiet down, and eating naturally shrinks. Tirzepatide adds a second hormone pathway (GIP), which in head-to-head trials produced greater average weight loss than semaglutide — at a correspondingly higher price point.
What results to realistically expect
In clinical studies, semaglutide averaged roughly 10–15% body-weight reduction over a year-plus of consistent use; tirzepatide reached about 15–20% at higher doses. Individual results vary widely with dose, adherence, food habits and activity — the medicine opens the door; routine walks through it.
Side effects — similar for both
The common effects are digestive: nausea, fullness, constipation or reflux, mostly in the first weeks and during dose increases. Slow titration, smaller meals and hydration manage most of it. Serious effects are rare; screening (pancreatitis history, thyroid cancer family history, pregnancy) is done before starting either program.
Which program fits which person?
- WegoSlim: budget-conscious start, moderate weight goal, or first GLP-1 experience
- MounjaSlim: larger weight goal, previous semaglutide plateau, or prioritising maximum effect
- Both: weekly self-injection with doctor follow-ups, dose titration and habit coaching
- Neither: pregnancy, certain endocrine histories, or BMI/goals better served another way — screening decides
The short version
- Same GLP-1 family; tirzepatide (MounjaSlim) averages more loss at a higher price.
- Digestive side effects are common early and manageable with slow titration.
- Doctor screening + follow-up is what separates a program from just buying a pen.
Frequently asked questions
Can I switch between the two programs?+
Yes — switching semaglutide ↔ tirzepatide is common (e.g. after a plateau). The doctor manages the transition dose safely.
Will the weight come back after stopping?+
Appetite returns when the medicine stops, so regain is possible without habit changes. Programs taper gradually and focus on eating routines you can keep — that is the real exit strategy.
How fast will I see results?+
Appetite changes within the first weeks; visible weight change typically from month 1–2, accelerating as the dose reaches its effective range.
Do I need to diet and exercise too?+
The medicine reduces hunger, but body composition and maintenance depend on protein intake, movement and sleep. Programs include this coaching for a reason.
Is buying pens online safe?+
Counterfeit and mis-stored pens are a real problem, and dosing without screening carries risk. A physician-run program exists precisely to remove those two dangers.
